CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Anaconda Biomed›
Library
Anaconda Biomed

Anaconda Biomed

Anaconda Biomed is a Spanish medical device company developing funnel catheter technology for stroke treatment.

HQ
Sant Quirze del Vallès, Barcelona, ES
Founded
2015
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Anaconda Biomed - Library

Official pages and third-party coverage in one index.

anaconda.bio·9 items·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Coverage

9 items
  1. Anaconda Biomed secures $56 million financing from new and existing investorsanaconda.bio/anaconda-biomed-secures-56-million-financing-from-new-and-existing-investors/

    Anaconda Biomed closes a $56 million financing round to advance its thrombectomy catheter program. The medical technology company is developing novel thrombectomy catheters based on its core funnel catheter platform, and says the proceeds will support completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized trial of 327 subjects evaluating the ANA Funnel Catheter.

    Sep 2026 · Anaconda BiomedNews article

  2. Anaconda Closes Financing to Support ATHENA Trial of ANA Funnel Catheterevtoday.com/news/anaconda-closes-financing-to-support-athena-trial-of-ana-funnel-catheter

    Anaconda Biomed closes a $56 million financing round to support its ANA funnel catheter trial. The proceeds will support completion of the 327-patient ATHENA pivotal investigational device exemption study of the ANA funnel catheter. Anaconda Biomed develops a portfolio of thrombectomy catheters based on its core funnel catheter technology platform.

    Sep 2026 · Endovascular TodayNews article

  3. ANA5 Funnel Catheter has received the CE Mark certificationanaconda.bio/ana5-funnel-catheter-has-received-the-ce-mark-certification/

    Anaconda Biomed receives CE Mark certification for its ANA5 Funnel Catheter, authorizing commercial distribution across Europe. Designed for mechanical thrombectomy in ischemic stroke, the catheter uses funnel-shaped geometry intended to maximize clot capture and improve first-pass recanalization rates.

    Jun 2025 · Anaconda BiomedNews article

  4. Anaconda Biomed Announces Publication of ANAIS Study Results in the American Journal of Neuroradiologybusinesswire.com/news/home/20250416628052/en/

    Anaconda Biomed reports that results from its ANAIS Study of the ANA funnel catheter are published in the American Journal of Neuroradiology. The study evaluates the catheter’s safety and performance in endovascular treatment of large vessel occlusion acute ischemic stroke, with data showing high reperfusion and first-pass success rates and a strong safety profile.

    Apr 2025 · Business WireNews article